drugset
drugset / Trial / NCT02140268

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

NCT02140268 ↗

Phase 1 Completed 65 enrolled Ardelyx
Non-randomizedSingle-groupOpen-labelBasic science

Summary

A Study to Evaluate the Effects of oral repeated doses of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

Timeline

Start
2014-05
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule 7.5 mg Oral
Subject Tenapanor Small molecule 15 mg —
Subject Tenapanor Small molecule 15 mg Oral

Indications

No indication recorded.